Get the Stockscreener App
2.01
11.05%
0.20
After Hours:
1.99
-0.02
-1.00%
Annexon Inc stock is traded at $2.01, with a volume of 1.76M.
It is up +11.05% in the last 24 hours and up +40.56% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$1.81
Open:
$1.81
24h Volume:
1.76M
Relative Volume:
1.07
Market Cap:
$220.52M
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-1.1356
EPS:
-1.77
Net Cash Flow:
$-121.34M
1W Performance:
+25.62%
1M Performance:
+40.56%
6M Performance:
-67.16%
1Y Performance:
-53.90%
1-Day Range:
$1.795
$2.05
1-Week Range:
$1.67
$2.05
52-Week Range:
$1.285
$7.85
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650)-822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.01 | 175.54M | 0 | -134.24M | -121.34M | -1.77 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | ANNX Stock News - GuruFocus
Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Annexon Awards $387K Worth of Stock Options to New Hires: Inside the Compensation Package - Stock Titan
HC Wainwright Issues Negative Estimate for Annexon Earnings - Defense World
HC Wainwright Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World
Needham & Company LLC Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Annexon (ANNX) Receives Revised Price Target from HC Wainwright - GuruFocus
Schonfeld Strategic Advisors LLC Sells 589,091 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Cantor Fitzgerald maintains Overweight on Annexon stock By Investing.com - Investing.com Nigeria
Annexon (ANNX) Sees Price Target Cut to $14 by H.C. Wainwright | - GuruFocus
Annexon Inc Reports Q1 2025 EPS of -$0.37, Missing Estimates; Re - GuruFocus
Annexon (ANNX) Maintains "Buy" Rating Despite Price Target Cut | ANNX Stock News - GuruFocus
Annexon Biosciences Reports Increased Q1 2025 Losses - TipRanks
Annexon, Inc. SEC 10-Q Report - TradingView
Annexon Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Annexon (ANNX) Advances with Promising Neurological and Vision T - GuruFocus
Annexon (ANNX) Financial Outlook Supported by Strong Cash Positi - GuruFocus
Annexon, Inc. Announces Upcoming FDA Meeting and Progress on Novel Therapies for Neurological and Ophthalmic Diseases - Nasdaq
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - GlobeNewswire
Hsbc Holdings PLC Has $156,000 Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Dimensional Fund Advisors LP Buys 231,034 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon stock hits 52-week low at $3.04 amid market challenges - MSN
Annexon Announces Presentations on the Clinical Advancement - GlobeNewswire
Annexon (ANNX) Expected to Announce Quarterly Earnings on Monday - Defense World
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting | ANNX Stock News - GuruFocus
Annexon, Inc. Reports Improved Outcomes for Tanruprubart in Guillain-Barré Syndrome at 2025 Peripheral Nerve Society Annual Meeting - Nasdaq
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting - Stock Titan
Annexon Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress - The Manila Times
Annexon to Present on the Neuroprotective Effects of ANX007 - GlobeNewswire
MetLife Investment Management LLC Boosts Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Barclays PLC - Defense World
Annexon Biosciences wants to Move GBS Forward in awareness push - Medical Marketing and Media
Invesco Ltd. Acquires 10,611 Shares of Annexon, Inc. (NASDAQ:ANNX) - The AM Reporter
Holdings of Annexon Inc (ANNX) are aligned with the stars - Sete News
What technical indicators reveal about ANNX stock - uspostnews.com
JP Morgan’s latest rating for ANNX stock - knoxdaily.com
Analytical Overview: Annexon Inc (ANNX)’s Ratios Tell a Financial Story - DWinneX
Legal & General Group Plc Acquires 71,665 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Wells Fargo & Company MN Boosts Stock Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Investors in cash trouble should check out Annexon Inc (ANNX) - Sete News
SEC Form DEFA14A filed by Annexon Inc. - Quantisnow
JP Morgan analysts upgrades an Overweight rating for Annexon Inc (ANNX) - knoxdaily.com
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Geode Capital Management LLC - Defense World
ANNX’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com
Annexon Inc (ANNX) Stock: A Year of Market Fluctuations - investchronicle.com
Alliancebernstein L.P. Reduces Stock Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Sees Large Decrease in Short Interest - Defense World
JPMorgan Chase & Co. Has $7.75 Million Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Annexon Inc Stock (ANNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER |
Feb 18 '25 |
Sale |
2.97 |
5,515 |
16,380 |
83,814 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Feb 18 '25 |
Sale |
2.91 |
8,345 |
24,284 |
61,237 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Feb 18 '25 |
Sale |
2.95 |
6,618 |
19,523 |
86,579 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Feb 18 '25 |
Sale |
2.92 |
6,912 |
20,183 |
77,770 |
| Love Douglas | PRESIDENT AND CEO |
Feb 13 '25 |
Sale |
2.95 |
5,021 |
14,812 |
351,554 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Feb 13 '25 |
Sale |
2.98 |
1,786 |
5,322 |
84,682 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Feb 13 '25 |
Sale |
2.99 |
1,425 |
4,261 |
93,197 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Feb 13 '25 |
Sale |
2.99 |
1,783 |
5,331 |
69,582 |
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):